SEARCH:   Advanced

Blood, 15 September 2005, Vol. 106, No. 6, pp. 2026-2032. Prepublished online as a Blood First Edition Paper on May 26, 2005; DOI 10.1182/blood-2005-03-0969. This Article Full Text (PDF) All Versions of this Article: 2005-03-0969v1 106/6/2026    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhou, H. Articles by Xiang, R. Search for Related Content PubMed PubMed Citation Articles by Zhou, H. Articles by Xiang, R. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 11, 2005 Accepted May 17, 2005 T cell-mediated suppression of angiogenesis results in tumor protective immunity He Zhou, Yunping Luo, Masato Mizutani, Noriko Mizutani, Ralph A Reisfeld, and Rong Xiang* Department of Immunology, The Scripps Research Institute, La Jolla, CA, USA * Corresponding author; email: rxiang{at}scripps.edu. Anti-angiogenic intervention is known to inhibit tumor growth and dissemination by attacking the tumor vascular supply. Here, we report that this was achieved for the first time using an oral DNA minigene vaccine against murine vascular endothelial growth factor receptor-2 (FLK-1), a self-antigen overexpressed on proliferating endothelial cells in the tumor vasculature. Moreover, we identified the first H-2Db-restricted epitope, FLK400 (VILTNPISM), specifically recognized by CTLs. Such CTLs were capable of killing FLK-1+ endothelial cells, resulting in suppression of angiogenesis and long-lived tumor protection. The specificity of this immune response was indicated as the DNA vaccine encoding the entire FLK-1 gene also induced a FLK400-specific CTL response. This minigene vaccine strategy provides a more flexible alternative to whole gene vaccination and facilitates in depth mechanism studies to tailor DNA vaccines for optimal T cell activation and tumor protection. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: The marriage of cancer vaccines and antiangiogenesis Jeffrey Schlom Blood 2005 106: 1897-1898. [Full Text] [PDF] This article has been cited by other articles: Y. Sun, M. Song, E. Jager, C. Schwer, S. Stevanovic, S. Flindt, J. Karbach, X. D. Nguyen, D. Schadendorf, and K. Cichutek Human CD4+ T Lymphocytes Recognize a Vascular Endothelial Growth Factor Receptor-2-Derived Epitope in Association with HLA-DR Clin. Cancer Res., July 1, 2008; 14(13): 4306 - 4315. [Abstract] [Full Text] [PDF] Y.-s. Wang, G.-q. Wang, Y.-j. Wen, L. Wang, X.-c. Chen, P. Chen, B. Kan, J. Li, C. Huang, Y. Lu, et al. Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine {beta}-Defensin 2 and mFlk-1 Clin. Cancer Res., November 15, 2007; 13(22): 6779 - 6787. [Abstract] [Full Text] [PDF] R. J. Petrovan, C. D. Kaplan, R. A. Reisfeld, and L. K. Curtiss DNA Vaccination Against VEGF Receptor 2 Reduces Atherosclerosis in LDL Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1095 - 1100. [Abstract] [Full Text] [PDF] X.-Y. Chen, W. Zhang, W. Zhang, S. Wu, F. Bi, Y.-J. Su, X.-Y. Tan, J.-N. Liu, and J. Zhang Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin. Cancer Res., October 1, 2006; 12(19): 5834 - 5840. [Abstract] [Full Text] [PDF] B. Kim, S. Suvas, P. P. Sarangi, S. Lee, R. A. Reisfeld, and B. T. Rouse Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects J. Immunol., September 15, 2006; 177(6): 4122 - 4131. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020